Modelling in economic evaluations of medicines

Dragana Lakić; Ivana Stević; Marina Odalović; Ivana Tadić

doi:10.5937/arhfarm71-32404

Dragana Lakić Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za socijalnu farmaciju i farmaceutsko zakonodavstvo
Ivana Stević Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za socijalnu farmaciju i farmaceutsko zakonodavstvo
Marina Odalović Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za socijalnu farmaciju i farmaceutsko zakonodavstvo
Ivana Tadić Univerzitet u Beogradu - Farmaceutski fakultet, Katedra za socijalnu farmaciju i farmaceutsko zakonodavstvo

DOI: https://doi.org/10.5937/arhfarm71-32404

Ključne reči: farmakoekonomske evaluacije, modelovanje, drvo odlučivanja, Markovljev model

Sažetak

Ekonomske evaluacije u zdravstvu (ili farmakoekonomija u slučaju lekova) identifikuju, vrednuju i mere troškove i ishode alternativnih zdravstvenih tehnologija, i mogu se sprovoditi paralelno sa kliničkim studijama, ali se češće primenjuje modelovanje. Drvo odlučivanja i Markovljev model su dva najčešće korišćena modela u ekonomskim evaluacijama. Najveća prednost primene drveta odlučivanja je njegova jednostavnost, jasnoća i direktnost. Sa druge strane, najveća prednost Markovljevog modela je sposobnost da uključi kompleksne događaje u simulaciju, što je praktično nemoguće sa drvetom odlučivanja. Ekonomske evaluacije su obavezan zahtev u nekoliko procesa u cilju povećanja dostupnosti lekova u Srbiji. Kako bi se pokazala sadašnja farmakoekonomska prednost leka neophodno je sprovesti analizu uticaja na budžet i analizu troškovne isplativosti. Drugu analizu je neophodno sprovesti primenom odgovarajuće tehnike modelovanja. Međutim, kako ne postoje zvanične smernice o modelovanju i ekonomskim evaluacija, dokumentacija podneta od strane nosioca dozvole pokazuje značajno variranje. Budućnost modelovanja u farmakoekonomiji zavisi od istraživačkog interesa, pri čemu se razvijaju novi okviri i pristupi.

Reference

Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd Ed. New York: Oxford University Press; 2005; p. 65-9.

Bootman JL, Townsend RJ, McGhan WF, editors. Principles of Pharmacoeconomics. 3rd Ed. Cincinnati: Harvey Whitney Books; 2005; p. 1-18.

Rascati KL. Essentials of Pharmacoeconomics. 2nd Ed. Philadelphia: Lippincott Williams & Wilkins; 2013; p. 3-6.

Petrou S, Gray A. Economic evaluation alongside randomised clinical trials: design, conduct, analysis, and reporting. BMJ. 2011;342:d1548.

Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295-310.

Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9(2):110-8.

Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.

Ademi Z, Kim H, Reid CM, Hollingsworth B, Liew D. Overview of pharmacoeconomic modelling methods. Br J Clin Pharmacol. 2012;75(4):944-50.

Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21.

Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. New York: Oxford University Press; 2010; p. 179-210.

Briggs A, Claxton C, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006; p. 27-44

Bogavac-Stanojevic N, Dopsaj V, Jelic-Ivanovic Z, Lakić D, Vasić D, Petrova G. Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis. Biochemia Medica 2013;23(1): 96-106.

Živković M, Lakić D, Tadić I, Odalović M, Bogavac Stanojević N. Farmakoekonomska evaluacija primene rastvora za infuziju kaspofungina i amfotericina B u terapiji teških sistemskih mikoza. Arh Farm 2015;65(1):33-46.

Lakić D, Tadić I, Odalović M, Kolundžić S. Upotreba antibakterijskih lekova u lečenju infekcija urinarnog trakta – farmakoekonomski aspekt. Arh Farm 2015;65(1):47-57.

Lakić D, Petrović B, Petrova G. A cost-effectiveness analysis of different types of labor for singleton pregnancy – real life data. Srp Arh Celok Lek 2014;142(11-12):688-94.

Stojković T, Marinković V, Lakić D, Bogavac-Stanojević N. Pharmacoeconomic Evaluation of Providing Pharmacist-Managed Anticoagulation Service to Patients on Warfarin. Arh farm 2016;66(2):103-17.

Basu S. Modelling Public Health and Healthcare Systems. New York: Oxford University Press; 2018; p. 125-45.

Cookson R, Griffin S, Norheim OF, Culyer A. Distributional Cost-Effectiveness Analysis. New York: Oxford University Press; 2021; p. 137-8.

Lakic D, Petrova G, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Kos M. The cost-effectiveness of hypertension pharmacotherapy in Serbia: A Markov Model. Biotechnol & Biotechnol Eq. 2012;26(3):3066-72.

Kostić M, Jovanović S, Tomović M, Milenković MP, Janković SM. Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition. Vojnosanit Pregl. 2014;71(2):144-8.

Kostić M, Milosavljević MN, Stefanović S, Ranković G, Janković SM. Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of Plasmodium vivaxmalaria. J Chemother. 2020;32(1):21-9.

Dutina A, Stašević-Karličić I, Pandrc N, Prokić A, Janković SM. Cost-effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia. Srp Arh Celok Lek. 2019;147(7-8):468-74.

Lakic D, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Kotur-Stevuljevic J, Spasic S, Kos M. A Multimarker Approach for the Prediction of Coronary Artery Disease: Cost-Effectiveness Analysis. Value Health. 2010;13(6):770-7.

Petrovic S, Bogavac-Stanojevic N, Lakic D, Peco-Antic AE, Vulicevic I, Ivanisevic I, et al. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. Biochemia Medica. 2015;25(2):262-71.

Uredba o kriterijumima za formiranje cena lekova za upotrebu u humanoj medicine čiji je režim izdavanja na recept. Službeni glasnik RS 86/15, 8/16, 15/18 and 18/19.

Pravilnik o uslovima, kriterijumima, načinu i postupku za stavljanje leka na listu lekova, izmene i dopune liste lekova, odnosno za skidanje leka sa Liste lekova. Službeni glasnik RS 41/14, 125/14, 48/15, and 14/18.

Cleemput I, Van Wilder P, Huybrechts M, Vrijens F. Belgian Methodological Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Requests. Value Health. 2009;12:441-9.

Piniazhko O, Zaliska O, Nemeth B. Development of Pharmacoeconomic Guidelines In Ukraine: Methodological Issues And Policy Implications. Value Health. 2017;20(9):A669-A700.

Squires H, Boyd K. The use of modelling approaches for the economic evaluation of public health intervention. In: Rhiannon T. Edwards, McIntosh E, editors. Applied health economics for public health practise and research. New York: Oxford University Press; 2019; p. 248-73.

Squirres, H, Chilcott J, Akehurst R, Burr J, Kelly MP. A framework for developing the structure of public health economic models. Value Health. 2016;19(5):588-601.

Boyd KA, Fenwick E, Briggs A. Using an Iterative Approach to Economic Evaluation in the Drug Development Process. Drug Develop Res. 2010;71(8):470–7.

Modelovanje u farmakoekonomskim evaluacijama lekova

Sažetak

Reference